Status:
UNKNOWN
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
Lead Sponsor:
Cairo University
Collaborating Sponsors:
German University in Cairo
Conditions:
Cisplatin Adverse Reaction
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity...
Eligibility Criteria
Inclusion
- Histologically proven lung and breast cancer patients indicated for cisplatin (4-6 cycles)
- Normal baseline serum creatinine levels
- Normal baseline audiometry
- Age between 18-70 years
Exclusion
- Patients with more than one type of cancer
- Patients with prior chemotherapy treatment
- Treatment with statins within 12 months before assignment
- Treatment with fibrates within 4 weeks before assignment
- Pregnancy and Lactation
- Abnormal liver function tests or blood count
Key Trial Info
Start Date :
November 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04817904
Start Date
November 17 2020
End Date
August 1 2021
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine
Cairo, Egypt